<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00416195</url>
  </required_header>
  <id_info>
    <org_study_id>E2007-G000-208</org_study_id>
    <secondary_id>2006-003702-26</secondary_id>
    <nct_id>NCT00416195</nct_id>
  </id_info>
  <brief_title>Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Explore the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, parallel group study to determine the
      maximum tolerated dose of E2007. Epilepsy patients with refractory partial seizures will be
      divided into two groups of 24 patients each. One group will be patients who take concomitant
      inducing AEDs (anti-epileptic drugs) and the second group will be patients who do not take
      concomitant inducing AEDs. In each group, 18 patients will receive E2007 (dose escalating to
      a maximum of 12 mg per day) and six will receive placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Responders During the Maintenance Phase</measure>
    <time_frame>Day 85 through Day 112</time_frame>
    <description>A patient is a responder if she/he experiences a 50% or greater reduction in seizure frequency from the baseline phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in the 28-day Seizure Frequency From Baseline in the Maintenance LOCF</measure>
    <time_frame>Baseline, Day 85 through Day 112</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>E2007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg E2007 once daily for 2 weeks (Days 1 to 14), then 4 mg E2007 once daily for 2 weeks (Days 15 to 28), then 6 mg E2007 once daily for 2 weeks (Days 29 to 42), then 8 mg E2007 once daily for 2 weeks (Days 43 to 56), then 10 mg E2007 once daily for 2 weeks (Days 57 to 70), then 12 mg E2007 once daily for 6 weeks (Days 71 to 112).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo once daily for 16 weeks (Days 1 to 112)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2007</intervention_name>
    <arm_group_label>E2007</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          1. Provide written informed consent signed by patient or legal guardian prior to entering
             the study or undergoing any study procedures.

          2. Are reliable and willing to make themselves available for the study period and are
             able to record seizures and report AEs themselves or have a caregiver who can record
             and report the events.

          3. Male and female patients will be eligible for enrollment. Females should be either of
             nonchildbearing potential as a result of surgery or menopause (1 year after onset), or
             of childbearing potential and practicing a medically acceptable method of
             contraception (e.g., abstinence, a barrier method plus spermicide, or intrauterine
             device [IUD]) for at least 1 month before Visit 1 (Screening) and for 1 month after
             the end of the study. They must also have a negative serum beta-human chorionic
             gonadotropin (B-hCG) at Screening. Those females using hormonal contraceptives must
             also be using an additional approved method of contraception (e.g., a barrier method
             plus spermicide or IUD) starting with the Baseline Phase and continuing throughout the
             entire study period.

          4. Are between the ages of 18 and 70 years of age, inclusive.

          5. Are of 40 kg (88 pounds) of weight or more.

          6. Have the diagnosis of epilepsy with partial seizures with or without secondarily
             generalized seizures according with the International League Against Epilepsy's
             Classification of Epileptic Seizures (1981). Diagnosis should have been established by
             clinical history, electroencephalogram and computed tomography/magnetic resonance
             imaging of the brain performed within the last 10 years and consistent with
             localization-related epilepsy.

          7. Have uncontrolled partial seizures despite having been treated with at least three
             different AEDs (given concurrently or sequentially) for at least 2 years.

          8. Have averaged at least three partial seizures per month, with no 21-day seizure-free
             period during the 2 months preceding randomization. This should be documented in the
             form of medical history, medical records, or photocopied records of the patient
             diary/patient chart. Simple partial seizures without motor signs will not be counted
             towards this inclusion criterion.

          9. Are currently being treated with one to three (maximum) marketed and approved AEDs and
             are known to take their medications as directed. Use of a vagal nerve stimulator is
             not considered an AED by this criterion.

         10. Are on a stable dose of the same AEDs for the 1 month prior to Visit 1.

         11. If using a vagal nerve stimulator, it must have been implanted at least 5 months prior
             to Visit 1. Stimulator parameters may not be changed for at least 1 month prior to
             Visit 1 or during the study. Magnet use will be allowed and documented throughout the
             study.

        EXCLUSION CRITERIA

          1. Have participated in a study involving administration of an investigational compound
             within 3 months of Visit 1 (Screening), or within 5 half-lives of the previous
             investigational compound, whichever is longer, or who have been previously treated
             with E2007.

          2. Presence of nonmotor simple partial seizures only.

          3. Presence of primary generalized epilepsies or seizures, such as absences, myoclonic
             epilepsies, Lennox-Gastaut syndrome.

          4. History of status epilepticus in the past year or seizure clusters where individual
             seizures cannot be counted.

          5. Show evidence of clinically significant disease (cardiac, respiratory,
             gastrointestinal, renal disease, etc) that, in the opinion of the investigator, could
             affect either the patient's safety or the conduct of the study.

          6. Show evidence of significant, active, hepatic disease. Stable elevations of liver
             enzymes, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) due to
             concomitant medications will be allowed if they are less than 2 times the ULN.

          7. Show evidence of significant active hematological disease such as a white blood cell
             (WBC) count &lt;= 2500/µL (2.50 1E+09/L), an absolute neutrophil count &lt;= 1000/µL (1.00
             1E+09/L), or a platelet count &lt;100,000/mm^3.

          8. Patients with clinically significant ECG abnormality, including prolonged QTc (defined
             as QTc &gt;=450 msec using Fridericia's correction).

          9. Presence of major active psychiatric disease. Patients taking a stable dose of
             selective serotonin reuptake inhibitor antidepressant (except fluvoxamine) will be
             allowed.

         10. Presence of a progressive central nervous system (CNS) disease, including degenerative
             CNS diseases and progressive tumors.

         11. Have a history of psychogenic seizures in the past 2 years.

         12. Pregnant or lactating females.

         13. Have a history of drug abuse in the past 2 years and/or positive finding on urinary
             drug screening, other than prescribed medication.

         14. Have a history of alcohol abuse in the past 2 years, and/or positive finding on
             urinary drug screen.

         15. Have had multiple drug allergies (dermatological, hematological, or organ toxicity) or
             one or more severe drug reactions.

         16. Allergy to lactose.

         17. Concomitant use of felbamate or use of felbamate within 2 months prior to Visit 1.

         18. Concomitant use or use within the 4 weeks prior to Visit 1 of neuroleptics, monoamine
             oxidase (MAO) inhibitors, barbiturates (except for seizure control indication),
             benzodiazepines (other than occasional intermittent use), and narcotic analgesics.

         19. Frequent need of rescue benzodiazepines (two or more times a month).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia Yang, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>P. Stradina Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gailezers</name>
      <address>
        <city>Riga</city>
        <zip>LV-1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Latvia</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2006</study_first_submitted>
  <study_first_submitted_qc>December 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2006</study_first_posted>
  <results_first_submitted>October 23, 2012</results_first_submitted>
  <results_first_submitted_qc>October 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 22, 2012</results_first_posted>
  <last_update_submitted>June 26, 2014</last_update_submitted>
  <last_update_submitted_qc>June 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matching placebo once daily for 16 weeks (Days 1 to 112)</description>
        </group>
        <group group_id="P2">
          <title>Perampanel</title>
          <description>2 mg perampanel once daily for 2 weeks (Days 1 to 14), then 4 mg perampanel once daily for 2 weeks (Days 15 to 28), then 6 mg perampanel once daily for 2 weeks (Days 29 to 42), then 8 mg perampanel once daily for 2 weeks (Days 43 to 56), then 10 mg perampanel once daily for 2 weeks (Days 57 to 70), then 12 mg perampanel once daily for 6 weeks (the last 2 weeks of the Titration Phase [Days 71 to 84] and a 4-week Maintenance Phase [Days 85 to 112])</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matching placebo once daily for 16 weeks (Days 1 to 112)</description>
        </group>
        <group group_id="B2">
          <title>Perampanel</title>
          <description>2 mg perampanel once daily for 2 weeks (Days 1 to 14), then 4 mg perampanel once daily for 2 weeks (Days 15 to 28), then 6 mg perampanel once daily for 2 weeks (Days 29 to 42), then 8 mg perampanel once daily for 2 weeks (Days 43 to 56), then 10 mg perampanel once daily for 2 weeks (Days 57 to 70), then 12 mg perampanel once daily for 6 weeks (the last 2 weeks of the Titration Phase [Days 71 to 84] and a 4-week Maintenance Phase [Days 85 to 112])</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" spread="12.05"/>
                    <measurement group_id="B2" value="40.7" spread="11.99"/>
                    <measurement group_id="B3" value="43.1" spread="12.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Responders During the Maintenance Phase</title>
        <description>A patient is a responder if she/he experiences a 50% or greater reduction in seizure frequency from the baseline phase.</description>
        <time_frame>Day 85 through Day 112</time_frame>
        <population>ITT population- all subjects in the Safety Population (all randomized subjects who took at least 1 dose of study drug) who had at least 2 weeks of baseline seizure frequency data and at least 1 week of seizure frequency data after baseline (LOCF - last observation carried forward)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo once daily for 16 weeks (Days 1 to 112)</description>
          </group>
          <group group_id="O2">
            <title>Perampanel</title>
            <description>2 mg perampanel once daily for 2 weeks (Days 1 to 14), then 4 mg perampanel once daily for 2 weeks (Days 15 to 28), then 6 mg perampanel once daily for 2 weeks (Days 29 to 42), then 8 mg perampanel once daily for 2 weeks (Days 43 to 56), then 10 mg perampanel once daily for 2 weeks (Days 57 to 70), then 12 mg perampanel once daily for 6 weeks (the last 2 weeks of the Titration Phase [Days 71 to 84] and a 4-week Maintenance Phase [Days 85 to 112])</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders During the Maintenance Phase</title>
          <description>A patient is a responder if she/he experiences a 50% or greater reduction in seizure frequency from the baseline phase.</description>
          <population>ITT population- all subjects in the Safety Population (all randomized subjects who took at least 1 dose of study drug) who had at least 2 weeks of baseline seizure frequency data and at least 1 week of seizure frequency data after baseline (LOCF - last observation carried forward)</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders (Yes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Responders (No)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6"/>
                    <measurement group_id="O2" value="65.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in the 28-day Seizure Frequency From Baseline in the Maintenance LOCF</title>
        <time_frame>Baseline, Day 85 through Day 112</time_frame>
        <population>ITT population (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo once daily for 16 weeks (Days 1 to 112)</description>
          </group>
          <group group_id="O2">
            <title>Perampanel</title>
            <description>2 mg perampanel once daily for 2 weeks (Days 1 to 14), then 4 mg perampanel once daily for 2 weeks (Days 15 to 28), then 6 mg perampanel once daily for 2 weeks (Days 29 to 42), then 8 mg perampanel once daily for 2 weeks (Days 43 to 56), then 10 mg perampanel once daily for 2 weeks (Days 57 to 70), then 12 mg perampanel once daily for 6 weeks (the last 2 weeks of the Titration Phase [Days 71 to 84] and a 4-week Maintenance Phase [Days 85 to 112])</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in the 28-day Seizure Frequency From Baseline in the Maintenance LOCF</title>
          <population>ITT population (LOCF)</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.4" lower_limit="-81.5" upper_limit="221.0"/>
                    <measurement group_id="O2" value="-35.4" lower_limit="-100.0" upper_limit="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching placebo once daily for 16 weeks (Days 1 to 112)</description>
        </group>
        <group group_id="E2">
          <title>Perampanel</title>
          <description>2 mg perampanel once daily for 2 weeks (Days 1 to 14), then 4 mg perampanel once daily for 2 weeks (Days 15 to 28), then 6 mg perampanel once daily for 2 weeks (Days 29 to 42), then 8 mg perampanel once daily for 2 weeks (Days 43 to 56), then 10 mg perampanel once daily for 2 weeks (Days 57 to 70), then 12 mg perampanel once daily for 6 weeks (the last 2 weeks of the Titration Phase [Days 71 to 84] and a 4-week Maintenance Phase [Days 85 to 112])</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA V. 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA V. 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Muscle contractions involuntary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eisai Inc.</name_or_title>
      <organization>Eisai Call Center</organization>
      <phone>888-422-4743</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

